trending Market Intelligence /marketintelligence/en/news-insights/trending/jLIBSNBjW9Yr06jvLq2REw2 content esgSubNav
In This List

Corindus Vascular stockholders approve $1.1B acquisition by Siemens Healthineers

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Corindus Vascular stockholders approve $1.1B acquisition by Siemens Healthineers

Corindus Vascular Robotics Inc. stockholders approved Siemens Healthineers AG's $1.1 billion acquisition of the company.

The Waltham, Mass.-based maker of robotic-assisted systems said stockholders also approved certain compensation to be paid to some of its executives in connection with the merger.

Germany's Siemens Healthineers announced the acquisition in August, agreeing to pay in cash $4.28 apiece for Corindus common stock and $85.60 apiece for series A and series A-1 preferred stocks.

Corindus will be delisted from the NYSE American once the transaction closes Oct. 29.

Citigroup Global Markets Inc. and Cadwalader Wickersham & Taft LLP advised Corindus on the deal.